/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is valued at a market cap of $27.7 billion.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and Biogen fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. Beyond its core neurology focus, the company is actively expanding its pipeline across immunology and rare diseases, leveraging cutting-edge modalities like antisense oligonucleotides (ASOs) to address high unmet medical needs.
This healthcare company is currently trading 5.5% below its 52-week high of $202.41, reached on Feb. 6. Shares of BIIB have gained 10.8% over the past three months, outperforming the State Street Health Care Select Sector SPDR ETF’s (XLV) marginal drop during the same time frame.
Moreover, on a YTD basis, shares of BIIB are up 8.6%, compared to XLV’s 1.4% fall. In the longer term, Biogen has soared 33.1% over the past 52 weeks, notably outpacing XLV’s 4.6% uptick over the same time frame.
To confirm its bullish trend, BIIB has been trading above its 200-day moving average since late August and has remained above its 50-day moving average since mid-August, with slight fluctuations.
On Feb. 6, BIIB shares advanced 8.5% following its stronger-than-expected Q4 earnings release. The company’s revenue declined 7.1% year over year to $2.3 billion, but surpassed the $2.2 billion analyst estimate. Meanwhile, its adjusted EPS came in at $1.99, handily exceeding consensus expectations of $1.63. Management credited the quarter’s performance to strong momentum in its newer product portfolio, particularly Leqembi, Skyclarys, Zurzuvae, and Qalsody, which together generated more than $1 billion in annual revenue.
BIIB has outperformed its rival, Amgen Inc. (AMGN), which gained 18.4% over the past 52 weeks. However, it has lagged AMGN’s 15.3% YTD rise.
Given Biogen’s recent outperformance, analysts remain moderately optimistic about its prospects. The stock has a consensus rating of "Moderate Buy” from the 35 analysts covering it, and the mean price target of $206.66 suggests an 8.6% premium to its current price levels.
